Physician profile
Guy Tillinghast
NPI 1205853793
$759.48
in general payments reported to CMS, 2019-2025
27 companies · $77.69 in 2025
The $77.69 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $233 · 2021: $28.46 · 2022: $15.02 · 2023: $257 · 2025: $77.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $141.73 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.23 | 2023 | |
| Merck Sharp & Dohme LLC | $49.06 | 2020-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $46.78 | 2019-2023 | Lunsumio, Columvi, Polivy |
| Regeneron Healthcare Solutions, INC. | $38.08 | 2019-2025 | Libtayo |
| Celgene Corporation | $34.27 | 2019-2020 | |
| Mirati Therapeutics, INC. | $29.49 | 2023 | Krazati |
| Janssen Biotech, INC. | $29.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.82 | 2019-2020 | |
| Caris Mpi, INC. | $26.55 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $26.01 | 2023 | |
| Morphosys, US INC. | $24.22 | 2023 | Monjuvi |
| Eisai INC. | $23.70 | 2023 | |
| Abbvie INC. | $21.25 | 2019 | |
| Daiichi Sankyo INC. | $20.72 | 2023 | Enhertu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.71 | 2019 | |
| Beone Medicines USA, INC. | $16.35 | 2025 | Brukinsa |
| Novo Nordisk INC | $15.96 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $15.84 | 2021 | |
| Seagen INC. | $15.02 | 2022 | |
| Emd Serono, INC. | $14.87 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.11 | 2020 | |
| Amgen INC. | $13.83 | 2023 | Xgeva, Vectibix, Nplate |
| Octapharma USA, INC. | $13.24 | 2019 | |
| Genzyme Corporation | $12.84 | 2020 | |
| Astellas Pharma US INC | $12.15 | 2020 | |
| Rigel Pharmaceuticals, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Tillinghast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.